First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.
For technical support, please send an email to: education@acmg.net or call 301-718-9603.
Or click on the "Help" icon on the left-hand side of your screen for more information.
ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
Therapy-related Neoplasms: Diagnosis and Clinical Perspectives
Tuesday, September 27, 2022
11:00am-12:00pm ET
www.acmgeducation.net
Course Description
Therapy-related neoplasms are recognized as a late effect of genotoxic exposure (cytotoxic chemotherapy or irradiation as a treatment for primary malignancy) or complication after solid organ transplant or treatment of autoimmune disorder. The importance of recognition of this type of neoplasms in oncology testing will be discussed in this session through a series of representative cases. These illustrative cases will demonstrate the utility of various axillary testing types in identification of markers associated with specific prognosis in this type of cancer and treatment options.
Target Audience
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
Agenda
Presentations followed by live Q&A.
Learning Objectives
At the conclusion of this session, participants should be able to:
- Discuss the clinicopathologic features of therapy-related neoplasms of myeloid and lymphoid origin.
- Identify genetic factors predisposing to therapy-related complications.
- Discuss the current status of clinical management of therapy-related neoplasms.
Moderator:
Beth Pitel, M.S., CG (ASCP) CM
Clinical Variant Scientist, Assistant Professor in Division of Laboratory Genetics and Genomics
Mayo Clinic, Rochester, MN
Presenters:
Yasmin Abaza, MD
Assistant Professor of Medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University
Dr. Yasmin Abaza earned her medical degree from University of Alexandria, Egypt and completed her Internal Medicine residency training at Florida Hospital Medical Center. She then completed two fellowships in Hematology/Oncology and Leukemia at UCLA and MD Anderson Cancer Center, respectively. She joined the Division of Hematology and Oncology, Leukemia Program, at Northwestern University in September 2020. Her research focuses on targeted therapies for patients with myeloid.
Juehua Gao, MD, PhD
Associate Professor of Pathology (Hematopathology), Feinberg School of Medicine, Northwestern University
Dr. Gao is an Associate Professor of Pathology at Northwestern University Feinberg School of Medicine. She earned her MD degree from Fudan University Shanghai College of Medicine in China, and PhD degree in Immunology from University of Florida. She completed her Anatomic and Clinical pathology residency, Hematopathology and Molecular Pathology fellowships at Northwestern University McGraw Medical Centre. She is board certified in Anatomic and Clinical pathology, Hematology and Molecular Genetic Pathology by American Board of Pathology. The focus of her clinical practice and research is hematologic malignancy.
Madina Sukhanova, PhD, FACMG
Assistant Professor of Pathology (Molecular Pathology), Feinberg School of Medicine, Northwestern University.
Dr. Madina Sukhanova earned her PhD degree in genetics from the Institute of Cytology and Genetics, Novosibirsk University, Russia and completed her clinical cytogenetics and molecular genetics fellowships at the University of Chicago. She has been with Division of Molecular Pathology at Northwestern Memorial Hospital since 2018 where she is the co-director of the cytogenetics laboratory and assistant technical director of molecular diagnostics laboratory. Her research work focuses on evidence-based subclassification of high-risk hematologic malignancies and identification of genetic markers of potential therapeutic significance.
Planning Committee:
Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP
Accredited Continuing Education Information
CME Educational Credits:
Accreditation
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Claiming your Educational Credits
Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.
Accredited Continuing Education Financial Disclosure
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.
ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACMG Education Policies
Please review the policies below regarding the ACMG Education program
All of the relevant financial relationships listed for these individuals have been mitigated.
NAME
|
ROLE
|
RELATIONSHIP/ COMPANY
|
|
Planning Member
|
Presenter Panelist Moderator
|
Peer Reviewer
|
|
Yasmin Abaza, MD
|
|
●
|
|
Consultant: Bristol-Myers Squibb Scientific Advisory Board: Kite Pharma, Inc, Pfizer
|
Manuela Benary, PhD
|
●
|
|
|
Nothing to Disclose.
|
Juehua Gao, MD, PhD
|
|
●
|
|
Nothing to Disclose.
|
Beth Pitel, MS, CG(ASCP)
|
●
|
|
|
Advisory Board – Qiagen, LLC
|
Gordana Raca, MD, PhD, FACMG
|
●
|
|
●
|
Nothing to Disclose.
|
Jane Radford, MHA, CHCP
|
●
|
|
|
Nothing to Disclose.
|
Jason Saliba, PhD
|
●
|
|
|
Nothing to Disclose.
|
Madina Sukhanova, PhD, FACMG
|
|
●
|
|
Nothing to Disclose.
|